Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
World Lung 2025 – Bristol seeks PRMT5 biomarkers
A common mutation comes into play for PRMT5 inhibition.
World Lung 2025 – backing for Bristol’s pivotal HER3 conjugate moves
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
World Lung 2025 – Candel looks to a new agla-vec use
But results come from a curated dataset, with no in-trial comparator.
Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
